Kevin M. Lalande

Kevin M. Lalande is a declared insider at 2 companies (board member); the most frequent names are Lumos Pharma, Inc. and Molecular Templates, Inc. Between 20 May 2021 and 12 December 2024, the trades on record add up to 11 filings.

Purchases make up the whole of the open-market record (8 purchases, €1.0M). Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 2 share grants.

Half of the purchases are above €105k and half below. Of 8 purchases, 8 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster.

The record was last updated on 13 December 2024 with a transaction in Lumos Pharma, Inc. The most recent open-market purchase was published on 21 June 2022, 1,580 days ago. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.